Details of the Drug

General Information of Drug (ID: DM0T3YH)

Drug Name
Indinavir
Synonyms
Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 613.8
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
65% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 18 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.20724 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.36% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.82 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.015 mg/mL [2]
Chemical Identifiers
Formula
C36H47N5O4
IUPAC Name
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
Canonical SMILES
CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
InChI
InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
InChIKey
CBVCZFGXHXORBI-PXQQMZJSSA-N
Cross-matching ID
PubChem CID
5362440
ChEBI ID
CHEBI:44032
CAS Number
150378-17-9
DrugBank ID
DB00224
TTD ID
D0V7CF
VARIDT ID
DR00299
INTEDE ID
DR0871
ACDINA ID
D00328

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Indinavir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Indinavir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Delavirdine DM3NF5G Moderate Decreased metabolism of Indinavir caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Fosamprenavir DM4W9B3 Minor Decreased metabolism of Indinavir caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Fostemsavir DM50ILT Moderate Decreased clearance of Indinavir due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [92]
Nevirapine DM6HX9B Moderate Increased metabolism of Indinavir caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [93]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Indinavir caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Efavirenz DMC0GSJ Moderate Increased metabolism of Indinavir caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [95]
Dolutegravir DMCZGRE Minor Decreased metabolism of Indinavir caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Etravirine DMGV8QU Moderate Increased metabolism of Indinavir caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Didanosine DMI2QPE Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [98]
Amprenavir DMLMXE0 Minor Decreased metabolism of Indinavir caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Darunavir DMN3GCH Moderate Decreased metabolism of Indinavir caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Maraviroc DMTL94F Major Decreased metabolism of Indinavir caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Ritonavir DMU764S Moderate Decreased metabolism of Indinavir caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
⏷ Show the Full List of 14 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Indinavir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Major Decreased metabolism of Indinavir caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [102]
Clindamycin DM15HL8 Moderate Decreased metabolism of Indinavir caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [103]
Tretinoin DM49DUI Moderate Decreased metabolism of Indinavir caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [104]
Repaglinide DM5SXUV Moderate Increased metabolism of Indinavir caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [105]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Indinavir caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [106]
Ivosidenib DM8S6T7 Major Decreased metabolism of Indinavir caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [107]
Midostaurin DMI6E0R Major Decreased metabolism of Indinavir caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [108]
Arn-509 DMT81LZ Moderate Increased metabolism of Indinavir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [93]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Indinavir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [109]
Oliceridine DM6MDCF Major Decreased metabolism of Indinavir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [110]
Mitotane DMU1GX0 Moderate Increased metabolism of Indinavir caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [93]
Terfenadine DM4KLPT Major Decreased metabolism of Indinavir caused by Terfenadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [111]
Donepezil DMIYG7Z Minor Decreased metabolism of Indinavir caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [112]
Ranolazine DM0C9IL Major Decreased metabolism of Indinavir caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [94]
Bepridil DM0RKS4 Moderate Decreased metabolism of Indinavir caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [90]
Dronedarone DMA8FS5 Major Decreased metabolism of Indinavir caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [94]
Nifedipine DMSVOZT Moderate Decreased metabolism of Indinavir caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [90]
Bedaquiline DM3906J Moderate Decreased metabolism of Indinavir caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [113]
Butalbital DM9J04X Moderate Increased metabolism of Indinavir caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [93]
Clorazepate DMC3JST Moderate Increased plasma concentrations of Indinavir and Clorazepate due to competitive inhibition of the same metabolic pathway. Anxiety disorder [6B00-6B0Z] [114]
Alprazolam DMC7XDN Major Decreased metabolism of Indinavir caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [90]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Indinavir caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [115]
Chlordiazepoxide DMTN5XI Moderate Increased plasma concentrations of Indinavir and Chlordiazepoxide due to competitive inhibition of the same metabolic pathway. Anxiety disorder [6B00-6B0Z] [114]
Clobazam - Lundbeck DMW1OQ0 Moderate Increased plasma concentrations of Indinavir and Clobazam - Lundbeck due to competitive inhibition of the same metabolic pathway. Anxiety disorder [6B00-6B0Z] [114]
Budesonide DMJIBAW Major Decreased metabolism of Indinavir caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [116]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Indinavir caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [117]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Indinavir caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [118]
Clarithromycin DM4M1SG Minor Decreased metabolism of Indinavir caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [119]
Rabeprazole DMMZXIW Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [120]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Indinavir caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [121]
Cariprazine DMJYDVK Major Decreased metabolism of Indinavir caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [122]
Erdafitinib DMI782S Major Decreased metabolism of Indinavir caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [123]
Pexidartinib DMS2J0Z Major Decreased metabolism of Indinavir caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [124]
Loperamide DMOJZQ9 Major Decreased metabolism of Indinavir caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [125]
Talazoparib DM1KS78 Moderate Decreased clearance of Indinavir due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [126]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Indinavir caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [127]
Lapatinib DM3BH1Y Major Decreased metabolism of Indinavir caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
HKI-272 DM6QOVN Major Decreased metabolism of Indinavir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
LY2835219 DM93VBZ Major Decreased metabolism of Indinavir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [129]
Esterified estrogens DM9KZDO Minor Decreased metabolism of Indinavir caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Tucatinib DMBESUA Moderate Decreased metabolism of Indinavir caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [130]
Palbociclib DMD7L94 Major Decreased metabolism of Indinavir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [131]
Quinestrol DMJ6H1Z Minor Decreased metabolism of Indinavir caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Indinavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
Toremifene DMQYUWG Major Decreased metabolism of Indinavir caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [132]
Bosutinib DMTI8YE Major Decreased metabolism of Indinavir caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Indinavir caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
Estradiol DMUNTE3 Minor Decreased metabolism of Indinavir caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Indinavir caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [133]
Atorvastatin DMF28YC Major Decreased metabolism of Indinavir caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [134]
Macitentan DMP79A1 Major Decreased metabolism of Indinavir caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [135]
Secobarbital DM14RF5 Moderate Increased metabolism of Indinavir caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [93]
PF-04449913 DMSB068 Major Decreased metabolism of Indinavir caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [136]
Fluorometholone DM2HKC4 Moderate Decreased metabolism of Indinavir caused by Fluorometholone mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [137]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Indinavir caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [138]
Salmeterol DMIEU69 Major Decreased metabolism of Indinavir caused by Salmeterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [94]
Revefenacin DMMP5SI Moderate Decreased clearance of Indinavir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [139]
Indacaterol DMQJHR7 Minor Decreased metabolism of Indinavir caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [140]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Indinavir caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [93]
Levomilnacipran DMV26S8 Major Decreased metabolism of Indinavir caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [141]
Regorafenib DMHSY1I Moderate Decreased metabolism of Indinavir caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [94]
Irinotecan DMP6SC2 Major Decreased metabolism of Indinavir caused by Irinotecan mediated inhibition of UGT. Colorectal cancer [2B91] [94]
Drospirenone DM1A9W3 Major Decreased metabolism of Indinavir caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [94]
Levonorgestrel DM1DP7T Minor Decreased metabolism of Indinavir caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [90]
Desogestrel DM27U4Y Minor Decreased metabolism of Indinavir caused by Desogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [142]
Ulipristal DMBNI20 Minor Decreased metabolism of Indinavir caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [126]
Mestranol DMG3F94 Minor Decreased metabolism of Indinavir caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [142]
Etonogestrel DMKA8J4 Minor Decreased metabolism of Indinavir caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [90]
Levobupivacaine DM783CH Moderate Decreased metabolism of Indinavir caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [126]
Lidocaine DML4ZOT Moderate Decreased metabolism of Indinavir caused by Lidocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [90]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Indinavir caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [143]
Alfentanil DMVO0UB Major Decreased metabolism of Indinavir caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [144]
Nimodipine DMQ0RKZ Major Decreased metabolism of Indinavir caused by Nimodipine mediated inhibition of CYP450 enzyme. Coronary vasospastic disease [BA85] [145]
Mifepristone DMGZQEF Major Decreased metabolism of Indinavir caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [146]
Osilodrostat DMIJC9X Major Decreased metabolism of Indinavir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [126]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Indinavir caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [93]
Ivacaftor DMZC1HS Major Decreased metabolism of Indinavir caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [94]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Indinavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [94]
Aprepitant DM053KT Moderate Decreased metabolism of Indinavir caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [147]
Vilazodone DM4LECQ Major Decreased metabolism of Indinavir caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Indinavir caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [149]
Escitalopram DMFK9HG Minor Decreased metabolism of Indinavir caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [150]
OPC-34712 DMHG57U Major Decreased metabolism of Indinavir caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Trazodone DMK1GBJ Moderate Decreased metabolism of Indinavir caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [152]
Mirtazapine DML53ZJ Moderate Decreased metabolism of Indinavir caused by Mirtazapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [153]
Griseofulvin DMK54YG Moderate Increased metabolism of Indinavir caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [93]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Indinavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [154]
[3H]estrone-3-sulphate DMGPF0N Minor Decreased metabolism of Indinavir caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [142]
Ospemifene DMC4GEI Moderate Decreased metabolism of Indinavir caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [155]
Ingrezza DMVPLNC Major Decreased metabolism of Indinavir caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [156]
Diazepam DM08E9O Moderate Increased plasma concentrations of Indinavir and Diazepam due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [114]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Indinavir caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [157]
Primidone DM0WX6I Moderate Increased metabolism of Indinavir caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Indinavir caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Cenobamate DMGOVHA Moderate Increased metabolism of Indinavir caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Stiripentol DMMSDOY Moderate Decreased metabolism of Indinavir caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [126]
Phenytoin DMNOKBV Moderate Increased metabolism of Indinavir caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Indinavir caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Clonazepam DMTO13J Moderate Increased plasma concentrations of Indinavir and Clonazepam due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [114]
Lacosamide DMVM6QR Moderate Decreased metabolism of Indinavir caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Carbamazepine DMZOLBI Moderate Increased metabolism of Indinavir caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Indinavir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Cannabidiol DM0659E Minor Decreased metabolism of Indinavir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [126]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Indinavir caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [90]
Bay 80-6946 DMLOS5R Major Decreased clearance of Indinavir due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [158]
Tazemetostat DMWP1BH Major Decreased metabolism of Indinavir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [159]
Solifenacin DMG592Q Major Decreased metabolism of Indinavir caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [94]
Mirabegron DMS1GYT Minor Decreased metabolism of Indinavir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [160]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Indinavir caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [161]
Darifenacin DMWXLYZ Major Decreased metabolism of Indinavir caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [94]
Itraconazole DMCR1MV Moderate Decreased metabolism of Indinavir caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [90]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Indinavir caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [94]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [120]
Omeprazole DM471KJ Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Omeprazole. Gastro-oesophageal reflux disease [DA22] [120]
Cisapride DMY7PED Major Decreased metabolism of Indinavir caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [162]
Ripretinib DM958QB Major Decreased metabolism of Indinavir caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [94]
Sunitinib DMCBJSR Moderate Decreased metabolism of Indinavir caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [94]
Avapritinib DMK2GZX Major Decreased metabolism of Indinavir caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [126]
Colchicine DM2POTE Major Decreased metabolism of Indinavir caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [163]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Indinavir caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [93]
Ergotamine DMKR3C5 Major Decreased metabolism of Indinavir caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [102]
Eplerenone DMF0NQR Major Decreased metabolism of Indinavir caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [94]
Simeprevir DMLUA9D Major Decreased metabolism of Indinavir caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Daclatasvir DMSFK9V Major Decreased metabolism of Indinavir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [126]
Isoniazid DM5JVS3 Minor Increased plasma concentrations of Indinavir and Isoniazid due to competitive inhibition of the same metabolic pathway. HIV-infected patients with tuberculosis [1B10-1B14] [90]
Rifampin DMA8J1G Major Increased metabolism of Indinavir caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [164]
Rifapentine DMCHV4I Major Increased metabolism of Indinavir caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [93]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Indinavir caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [126]
Simvastatin DM30SGU Major Decreased metabolism of Indinavir caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [134]
Lovastatin DM9OZWQ Major Decreased metabolism of Indinavir caused by Lovastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [134]
BMS-201038 DMQTAGO Major Decreased metabolism of Indinavir caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [94]
Cerivastatin DMXCM7H Major Decreased metabolism of Indinavir caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [134]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Indinavir caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [165]
Paricalcitol DMYBV3G Moderate Decreased metabolism of Indinavir caused by Paricalcitol mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [126]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [126]
Aliskiren DM1BV7W Moderate Decreased clearance of Indinavir due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [166]
Nisoldipine DM7ISKJ Moderate Decreased metabolism of Indinavir caused by Nisoldipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Levamlodipine DM92S6N Moderate Decreased metabolism of Indinavir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Doxazosin DM9PLRH Moderate Decreased metabolism of Indinavir caused by Doxazosin mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [166]
Isradipine DMA5XGH Moderate Decreased metabolism of Indinavir caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Verapamil DMA7PEW Moderate Decreased metabolism of Indinavir caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Indinavir caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Amlodipine DMBDAZV Moderate Decreased metabolism of Indinavir caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Felodipine DMOSW35 Moderate Decreased metabolism of Indinavir caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Conivaptan DM1V329 Major Decreased metabolism of Indinavir caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [94]
Tolvaptan DMIWFRL Major Decreased metabolism of Indinavir caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [94]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Indinavir caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [167]
Levothyroxine DMHN027 Moderate Decreased metabolism of Indinavir caused by Levothyroxine mediated inhibition of UGT. Hypo-thyroidism [5A00] [168]
Retapamulin DM9JXB7 Minor Decreased metabolism of Indinavir caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [169]
Lesinurad DMUR64T Moderate Increased metabolism of Indinavir caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [93]
TP-434 DM5A31S Minor Decreased metabolism of Indinavir caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [170]
Suvorexant DM0E6S3 Major Decreased metabolism of Indinavir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Amobarbital DM0GQ8N Moderate Increased metabolism of Indinavir caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Ramelteon DM7IW9J Moderate Decreased metabolism of Indinavir caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [171]
Eszopiclone DM8RZ9H Major Decreased metabolism of Indinavir caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [172]
Flurazepam DMAL4G0 Moderate Increased plasma concentrations of Indinavir and Flurazepam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [114]
Butabarbital DMC5AST Moderate Increased metabolism of Indinavir caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Triazolam DMETYK5 Major Decreased metabolism of Indinavir caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [134]
Pentobarbital DMFNH7L Moderate Increased metabolism of Indinavir caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Indinavir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [173]
ITI-007 DMUQ1DO Major Decreased metabolism of Indinavir caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [174]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Indinavir caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [175]
Quazepam DMY4D87 Moderate Increased plasma concentrations of Indinavir and Quazepam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [114]
Estazolam DMZGXUM Moderate Increased plasma concentrations of Indinavir and Estazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [114]
Alosetron DML2A03 Moderate Decreased metabolism of Indinavir caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [176]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Indinavir caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [177]
Naloxegol DML0B41 Major Decreased metabolism of Indinavir caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [94]
Pemigatinib DM819JF Major Decreased metabolism of Indinavir caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [126]
Crizotinib DM4F29C Major Decreased metabolism of Indinavir caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [94]
Brigatinib DM7W94S Major Decreased metabolism of Indinavir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [178]
Ceritinib DMB920Z Major Decreased metabolism of Indinavir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [94]
Erlotinib DMCMBHA Moderate Decreased metabolism of Indinavir caused by Erlotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [179]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Indinavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [180]
PF-06463922 DMKM7EW Major Decreased metabolism of Indinavir caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [181]
Osimertinib DMRJLAT Major Decreased metabolism of Indinavir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [182]
Pralsetinib DMWU0I2 Major Decreased metabolism of Indinavir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [183]
Capmatinib DMYCXKL Major Decreased metabolism of Indinavir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [184]
Selpercatinib DMZR15V Major Decreased metabolism of Indinavir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [126]
Halofantrine DMOMK1V Major Decreased metabolism of Indinavir caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [185]
Chloroquine DMSI5CB Moderate Decreased metabolism of Indinavir caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [94]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Indinavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [94]
Quinine DMSWYF5 Moderate Decreased metabolism of Indinavir caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [94]
GDC-0199 DMH0QKA Major Decreased metabolism of Indinavir caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [186]
IPI-145 DMWA24P Major Decreased metabolism of Indinavir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [187]
Acalabrutinib DM7GCVW Major Decreased metabolism of Indinavir caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [188]
Ibrutinib DMHZCPO Major Decreased metabolism of Indinavir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [94]
Vincristine DMINOX3 Major Decreased metabolism of Indinavir caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [189]
Ponatinib DMYGJQO Major Decreased metabolism of Indinavir caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [94]
Arry-162 DM1P6FR Moderate Decreased clearance of Indinavir due to the transporter inhibition by Arry-162. Melanoma [2C30] [94]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Indinavir caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [190]
Selumetinib DMC7W6R Major Decreased metabolism of Indinavir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [191]
LGX818 DMNQXV8 Major Decreased metabolism of Indinavir caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [192]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Indinavir caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [94]
Estrone DM5T6US Minor Decreased metabolism of Indinavir caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [90]
Dienestrol DMBSXI0 Minor Decreased metabolism of Indinavir caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [142]
Conjugated estrogens DMLT0E1 Minor Decreased metabolism of Indinavir caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [90]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Indinavir caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [142]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Indinavir caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [166]
Methysergide DM1EF73 Major Decreased metabolism of Indinavir caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [102]
Dihydroergotamine DM5IKUF Major Decreased metabolism of Indinavir caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [102]
Ubrogepant DM749I3 Major Decreased metabolism of Indinavir caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [193]
Almogran DM7I64Z Moderate Decreased metabolism of Indinavir caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [194]
Rimegepant DMHOAUG Moderate Decreased metabolism of Indinavir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [195]
Exjade DMHPRWG Moderate Decreased metabolism of Indinavir caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [196]
Flibanserin DM70DTN Major Decreased metabolism of Indinavir caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [197]
Midazolam DMXOELT Major Decreased metabolism of Indinavir caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [134]
Panobinostat DM58WKG Major Decreased metabolism of Indinavir caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [198]
Siponimod DM2R86O Major Decreased metabolism of Indinavir caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [94]
Deflazacort DMV0RNS Major Decreased metabolism of Indinavir caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [126]
Rifabutin DM1YBHK Major Increased metabolism of Indinavir caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [199]
Bexarotene DMOBIKY Moderate Increased metabolism of Indinavir caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [93]
Romidepsin DMT5GNL Moderate Decreased metabolism of Indinavir caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [200]
Fedratinib DM4ZBK6 Major Decreased metabolism of Indinavir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [126]
Nilotinib DM7HXWT Major Decreased metabolism of Indinavir caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [94]
Ruxolitinib DM7Q98D Major Decreased metabolism of Indinavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [201]
Imatinib DM7RJXL Moderate Decreased metabolism of Indinavir caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [202]
Dasatinib DMJV2EK Major Decreased metabolism of Indinavir caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [94]
Vorapaxar DMA16BR Major Decreased metabolism of Indinavir caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [94]
Modafinil DMYILBE Moderate Increased metabolism of Indinavir caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [203]
Droperidol DM0DXA8 Moderate Decreased metabolism of Indinavir caused by Droperidol mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [167]
Netupitant DMEKAYI Minor Decreased metabolism of Indinavir caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [204]
E-2007 DMJDYNQ Minor Decreased metabolism of Indinavir caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [126]
Entrectinib DMMPTLH Major Decreased metabolism of Indinavir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [94]
Sibutramine DMFJTDI Minor Decreased metabolism of Indinavir caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [205]
Orlistat DMRJSP8 Moderate Altered absorption of Indinavir caused by Orlistat. Obesity [5B80-5B81] [206]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Indinavir caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [207]
S-297995 DM26IH8 Moderate Decreased metabolism of Indinavir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [126]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Indinavir caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [208]
Olaparib DM8QB1D Major Decreased metabolism of Indinavir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [94]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Indinavir caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [209]
Butorphanol DM5KYPJ Major Decreased metabolism of Indinavir caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [210]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Indinavir caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [211]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Indinavir caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [212]
Oxycodone DMXLKHV Major Decreased metabolism of Indinavir caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [94]
Istradefylline DM20VSK Major Decreased metabolism of Indinavir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [213]
Pimavanserin DMR7IVC Major Decreased metabolism of Indinavir caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [214]
Abametapir DM2RX0I Moderate Decreased metabolism of Indinavir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [215]
Esomeprazole DM7BN0X Moderate Decreased absorption of Indinavir due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [120]
Lefamulin DME6G97 Major Decreased clearance of Indinavir due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [216]
Prednisone DM2HG4X Moderate Decreased metabolism of Indinavir caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [167]
Betamethasone DMAHJEF Moderate Decreased metabolism of Indinavir caused by Betamethasone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [167]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Indinavir caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [167]
Ergonovine DM0VEC1 Major Decreased metabolism of Indinavir caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [102]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Indinavir caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [217]
Progesterone DMUY35B Minor Decreased metabolism of Indinavir caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [90]
ABIRATERONE DM8V75C Minor Decreased metabolism of Indinavir caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [218]
Enzalutamide DMGL19D Moderate Increased metabolism of Indinavir caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [93]
Darolutamide DMV7YFT Moderate Decreased clearance of Indinavir due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [219]
Tamsulosin DM5QF9V Major Decreased metabolism of Indinavir caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [94]
Silodosin DMJSBT6 Major Decreased metabolism of Indinavir caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [94]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Indinavir caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [220]
Alfuzosin DMZVMKF Major Decreased metabolism of Indinavir caused by Alfuzosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [94]
Ambrisentan DMD1QXW Minor Decreased metabolism of Indinavir caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [221]
Bosentan DMIOGBU Moderate Increased metabolism of Indinavir caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [94]
Riociguat DMXBLMP Moderate Decreased clearance of Indinavir due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [94]
Everolimus DM8X2EH Major Decreased metabolism of Indinavir caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [94]
Axitinib DMGVH6N Major Decreased metabolism of Indinavir caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [94]
Temsirolimus DMS104F Major Increased metabolism of Indinavir caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [94]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Indinavir caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [167]
Upadacitinib DM32B5U Major Decreased metabolism of Indinavir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [222]
Tofacitinib DMBS370 Major Decreased metabolism of Indinavir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [94]
Dexamethasone DMMWZET Moderate Decreased metabolism of Indinavir caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [94]
Nafcillin DMN9RPO Moderate Increased metabolism of Indinavir caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [93]
Quetiapine DM1N62C Major Decreased metabolism of Indinavir caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [223]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Indinavir caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [224]
Iloperidone DM6AUFY Major Decreased metabolism of Indinavir caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [225]
Ziprasidone DMM58JY Minor Decreased metabolism of Indinavir caused by Ziprasidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [226]
Pimozide DMW83TP Major Decreased metabolism of Indinavir caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [94]
Fentanyl DM8WAHT Major Decreased metabolism of Indinavir caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [94]
Sufentanil DMU7YEL Moderate Decreased metabolism of Indinavir caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [227]
Avanafil DM75CXN Major Decreased metabolism of Indinavir caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [94]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Indinavir caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [228]
Vardenafil DMTBGW8 Major Decreased metabolism of Indinavir caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [229]
Voxelotor DMCS6M5 Major Decreased metabolism of Indinavir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [230]
LDE225 DMM9F25 Major Decreased metabolism of Indinavir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [231]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Indinavir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [126]
Gefitinib DM15F0X Moderate Decreased metabolism of Indinavir caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [179]
Larotrectinib DM26CQR Major Decreased metabolism of Indinavir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [94]
Methylprednisolone DM4BDON Major Decreased metabolism of Indinavir caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [167]
Vinblastine DM5TVS3 Major Decreased metabolism of Indinavir caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [189]
Docetaxel DMDI269 Major Decreased metabolism of Indinavir caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [232]
Trabectedin DMG3Y89 Major Decreased metabolism of Indinavir caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [94]
Armodafinil DMGB035 Moderate Increased metabolism of Indinavir caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [203]
LEE011 DMMX75K Major Decreased metabolism of Indinavir caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [126]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Indinavir caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [167]
Norethindrone DMTY169 Minor Decreased metabolism of Indinavir caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [142]
Taxol DMUOT9V Major Decreased metabolism of Indinavir caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [233]
Vinorelbine DMVXFYE Major Decreased clearance of Indinavir due to the transporter inhibition by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [189]
Pitolisant DM8RFNJ Moderate Increased metabolism of Indinavir caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [126]
Ivermectin DMDBX5F Moderate Decreased metabolism of Indinavir caused by Ivermectin mediated inhibition of CYP450 enzyme. Strongyloidiasis [1F6B] [126]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Indinavir caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [94]
Fostamatinib DM6AUHV Major Decreased metabolism of Indinavir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [234]
As-1670542 DMV05SW Moderate Decreased metabolism of Indinavir caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [126]
Apixaban DM89JLN Moderate Decreased clearance of Indinavir due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [126]
Brilinta DMBR01X Major Decreased metabolism of Indinavir caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [94]
Cabozantinib DMIYDT4 Major Decreased metabolism of Indinavir caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [94]
Sirolimus DMGW1ID Major Decreased clearance of Indinavir due to the transporter inhibition by Sirolimus. Transplant rejection [NE84] [94]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Indinavir caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [235]
Saxagliptin DMGXENV Moderate Decreased metabolism of Indinavir caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [126]
Elagolix DMB2C0E Major Decreased metabolism of Indinavir caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [236]
Diethylstilbestrol DMN3UXQ Minor Decreased metabolism of Indinavir caused by Diethylstilbestrol mediated inhibition of CYP450 enzyme. Vaginitis [GA02] [90]
Astemizole DM2HN6Q Major Decreased metabolism of Indinavir caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [111]
Triamcinolone DM98IXF Major Decreased metabolism of Indinavir caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [167]
Fluticasone DMGCSVF Major Decreased metabolism of Indinavir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [237]
Disopyramide DM5SYZP Major Decreased metabolism of Indinavir caused by Disopyramide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [238]
Propafenone DMPIBJK Moderate Decreased metabolism of Indinavir caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [239]
Amiodarone DMUTEX3 Major Decreased metabolism of Indinavir caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [166]
⏷ Show the Full List of 307 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Gelatin E00630 Not Available Other agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Indinavir Sulfate eq 400mg base capsule eq 400mg base Capsule Oral
Indinavir 200 mg capsule 200 mg Oral Capsule Oral
Indinavir 400 mg capsule 400 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
7 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
8 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9 HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
12 Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R738-43.
13 Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
14 Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
24 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
25 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
26 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
27 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
28 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
29 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
30 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
31 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
32 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
33 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
34 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
35 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
36 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
37 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
38 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
39 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
40 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
41 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
42 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
43 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
44 Drug Interactions Flockhart Table
45 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
46 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
47 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
48 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
49 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
50 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
51 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
52 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
53 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
54 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
55 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
56 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
57 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
58 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
59 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
60 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
61 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
62 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
63 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
64 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
65 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
66 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
67 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
68 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
69 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
70 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
71 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
72 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
73 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
74 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
75 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
76 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
77 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
78 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
79 PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
80 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
81 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
82 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
83 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
84 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
85 Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
86 2011 Pipeline of Boehringer Ingelheim Pharma.
87 2011 Pipeline of Bristol-Myers Squibb.
88 2011 Pipeline of InterMune.
89 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
90 Product Information. Crixivan (indinavir). Merck & Co, Inc, West Point, PA.
91 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
92 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
93 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
94 Cerner Multum, Inc. "Australian Product Information.".
95 Aarnoutse RE, Grintjes KJ, Telgt DS, et al. "The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers." Clin Pharmacol Ther 71 (2002): 57-67. [PMID: 11823758]
96 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
97 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
98 Product Information. Videx (didanosine). Bristol-Myers Squibb, Princeton, NJ.
99 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
100 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
101 Aarnoutse RE, Wasmuth JC, Fatkenheuer G, et al. "Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir." Antivir Ther 8 (2003): 309-14. [PMID: 14518700]
102 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
103 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
104 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
105 Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4. [PMID: 9291911]
106 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
107 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
108 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
109 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
110 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
111 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
112 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
113 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
114 Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
115 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
116 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
117 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
118 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
119 Boruchoff SE, Sturgill MG, Grasing KW, et al. "The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin." Clin Pharmacol Ther 67 (2000): 351-9. [PMID: 10801243]
120 Burger DM, Hugen PWH, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA "Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir." AIDS 12 (1998): 2080-2. [PMID: 9814882]
121 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
122 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
123 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
124 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
125 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
126 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
127 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
128 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
129 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
130 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
131 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
132 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
133 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
134 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
135 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
136 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
137 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
138 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
139 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
140 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
141 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
142 Product Information. Crixivan (indinavir). Merck &amp Co, Inc, West Point, PA.
143 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
144 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
145 Product Information. Nimotop (nimodipine). Bayer, West Haven, CT.
146 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
147 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
148 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
149 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
150 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
151 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
152 Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
153 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
154 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
155 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
156 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
157 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
158 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
159 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
160 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
161 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
162 Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8. [PMID: 7695465]
163 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
164 McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB "Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis." Am J Respir Crit Care Med 154 (1996): 1462-7. [PMID: 8912765]
165 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
166 Canadian Pharmacists Association.
167 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
168 Lanzafame M, Trevenzoli M, Faggian F, et al. "Interaction between levothyroxine and indinavir in a patient with HIV infection." Infection 30 (2002): 54-5. [PMID: 11876520]
169 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
170 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
171 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
172 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
173 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
174 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
175 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
176 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
177 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
178 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
179 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
180 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
181 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
182 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
183 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
184 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
185 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
186 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
187 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
188 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
189 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
190 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
191 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
192 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
193 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
194 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
195 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
196 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
197 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
198 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
199 American Thoracic Society, CDC, Infectious Diseases Society of America "Treatment of tuberculosis." MMWR Morb Mortal Wkly Rep 52(RR-11) (2003): 1-77. [PMID: 12836625]
200 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
201 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
202 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
203 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
204 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
205 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
206 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
207 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
208 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
209 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
210 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
211 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
212 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
213 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
214 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
215 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
216 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
217 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
218 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
219 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
220 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
221 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
222 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
223 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
224 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
225 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
226 Miceli JJ, Smith M, Robarge L, Morse T, Laurent A "The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s71-6. [PMID: 10771458]
227 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
228 Loulergue P, Gaillard R, Mir O "Interaction involving tadalafil and CYP3A4 inhibition by ritonavir." Scand J Infect Dis 43 (2011): 239-40. [PMID: 20942777]
229 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
230 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
231 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
232 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
233 Bundow D, Aboulafia DM "Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma." Am J Clin Oncol 27 (2004): 81-4. [PMID: 14758138]
234 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
235 Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5. [PMID: 19709321]
236 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
237 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
238 Product Information. Norpace (disopyramide). Searle, Skokie, IL.
239 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.